Etalocib
Alternative Names: LY-293111; VML 295Latest Information Update: 09 Apr 2021
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; Vernalis
- Class Anti-inflammatories; Antineoplastics; Benzoic acids
- Mechanism of Action 5-lipoxygenase inhibitors; Leukotriene B4 receptor antagonists; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Asthma; Non-small cell lung cancer; Pancreatic cancer; Psoriasis; Ulcerative colitis
Most Recent Events
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
- 22 Jul 2011 Discontinued - Phase-II for Non-small cell lung cancer in Canada (PO)
- 22 Jul 2011 Discontinued - Phase-II for Non-small cell lung cancer in Europe (PO)